

AMENDMENT  
- 21 -

## CLAIMS:-

1. A pharmaceutical composition for protection of an animal against a disease-causing agent, the composition comprising  
5 a non-infectious nucleic acid construct encoding a recombinant antibody to that agent.

2. A pharmaceutical composition according to claim 1 wherein  
the animal is a mammal or a fish.

10 3. A pharmaceutical composition according to either of claims 1 or 2 wherein the animal has a deficient immune system.

15 4. A pharmaceutical composition according to any preceding claim wherein the disease-causing agent is a pathogen, an allergen or a toxic substance.

5. A pharmaceutical composition according to any preceding  
20 claim wherein the protection is prophylactic.

6. A pharmaceutical composition according to any preceding claim wherein the encoded recombinant antibody is derived from an antibody raised against the disease-causing agent.

25 7. A pharmaceutical composition according to any preceding claim wherein the encoded antibody molecule comprises variable domains of immunoglobulin Heavy and Light chain genes linked together by a linker sequence.

30 8. A pharmaceutical composition according to any preceding claim, wherein the nucleic acid construct further comprises a gene sequence encoding a secretion signal peptide.

BEST AVAILABLE COPY

AMENDED SHEET

Empf.zeit:21/11/2001 14:40

DRAFT.01.07.1.004

- 22 -

9. A pharmaceutical composition according to any preceding claim comprising genes encoding antibody molecules to several different epitopes of the disease-causing agent.

5 10. A pharmaceutical composition according to any preceding claim comprising a gene-expression library encoding antibodies to the disease-causing agent.

11. A pharmaceutical composition according to claim 10  
10 wherein the gene expression library encodes single-chain antibody molecules to the disease-causing agent.

12. A pharmaceutical composition according to any preceding claim wherein the encoded recombinant antibody is a virus-  
15 neutralising antibody.

13. A pharmaceutical composition according to claim 12  
wherein the encoded virus-neutralising antibody is single chain molecule.

20

14. A pharmaceutical composition according to any preceding claim including a nucleic acid construct encoding a viral haemorrhagic septicaemia virus VHSV-neutralising monoclonal antibody 3F1H10 with two amino acids substituents in the H-  
25 chain gene respectively Asn 35a to Thr and Lys 64 to Thr and with the secretion signal of rainbow trout transforming growth factor (TGF-beta) added to the 5' end of the gene.

15. A pharmaceutical composition according to any of claims  
30 4 to 11 wherein when the disease-causing agent is an allergen the antibody molecule is derived from an antibody raised against IgE molecules.

**BEST AVAILABLE COPY**

- 23 -

16. A pharmaceutical composition according to any preceding claim wherein the nucleic acid construct is formed from DNA.

17. A pharmaceutical composition according to any preceding  
5 claim wherein the composition is in the form of a vaccine,  
dosage form, cream, ointment, liquid or paint.

18. A pharmaceutical composition according to any preceding  
claim wherein the composition is for delivery by injection,  
10 spray or gene gun.

19. A method of treating an animal comprising administering thereto a pharmaceutical composition as claimed in any of claims 1 to 18.

15

20. A pharmaceutical composition according to any preceding claim, for use to confer protection against a disease caused by a pathogen, an allergen or a toxin.

add  
7

**BEST AVAILABLE COPY**

AMENDED SHEET

AMENDED  
Emef-zeit:21/14/2011 14:49

EMPT-DR-10// E-JUN